By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
Schneider Shorts of 3.07.2026 – a Georgian dream in Switzerland, a German professor who overdid his papermilling, a Chinese refugee chased by retractions, a great Italian who discovered Imanitib, and the mystery question of who is protecting a US-Iranian fraudster from retractions?
“PCR reactions run on agarose gels commonly look similar due to artifacts introduced by the agarose gel and comb.” Dr Elsa R Flores, Associate Director, Moffitt Cancer Center
An academic dynasty of bad cancer research.
“In October of this year, the scientist who closed the American laboratory, disposed of related assets in the United States, and returned to Shanghai with his wife to start a business, officially opened the mode of “wholeheartedly” returning to his country to start a business.”
“IU School of Medicine scientists discover ‘game-changer’ treatment for triple negative breast cancer”
The new ERC President Mauro Ferrari used to closely collaborate with two very controversial cancer researchers at MD Anderson in Texas: Anil Sood and Gabriel Lopez-Beerestein. Will that experience affect ERC’s already wanting stance on research integrity?
“The graduate school at University of Texas MD Anderson does not care and keep sending students to his lab, Sood is a member of faculty there. RIO at MDACC doesn’t care because witnesses either left the country or are too afraid to speak.”
For Better Science